Showing 801 - 820 results of 3,755 for search '"glucose"', query time: 0.07s Refine Results
  1. 801
  2. 802
  3. 803
  4. 804

    Association between the cumulative estimated glucose disposal rate and incident cardiovascular disease in individuals over the age of 50 years and without diabetes: data from two large cohorts in China and the United States by Jin Zhang, Ziyi Sun, Yufei Li, Yuhan Yang, Wenjie Liu, Mengwen Huang, Kuiwu Yao

    Published 2025-01-01
    “…Abstract Background The estimated glucose disposal rate (eGDR) has been linked to incident cardiovascular disease (CVD) in individuals without diabetes. …”
    Get full text
    Article
  5. 805

    The oral disposition index calculated from a meal tolerance test is a crucial indicator for evaluating differential normalization of postprandial glucose and triglyceride excursions in morbidly obese patients after laparoscopic sleeve gastrectomy by Yukako Yamamoto, Takeshi Togawa, Osamu Sekine, Yuki Ozamoto, Junko Fuse, Choka Azuma, Jun Ito-Kobayashi, Yasumitsu Oe, Akeo Hagiwara, Masaki Kobayashi, Tadahiro Kitamura, Masanori Iwanishi, Akira Shimatsu, Atsunori Kashiwagi

    Published 2023-12-01
    “…To determine the normalization of postprandial blood glucose (PG) and triglyceride (TG) excursions in 30 morbidly obese patients with or without diabetes mellitus (DM) 1-year after they underwent a laparoscopic sleeve gastrectomy (LSG) vs. their pre-surgery data, we administered the 75-g oral glucose tolerance test (OGTT) and a meal tolerance test (MTT) using a 75-g glucose-equivalent carbohydrate- and fat-containing meal. …”
    Get full text
    Article
  6. 806

    Sodium glucose co-transporter 2 (SGLT2) inhibitors versus dipeptidyl peptidase-4 (DPP-4) inhibitors and the risk of Atrial Fibrillation in patients with type 2 diabetes mellitus: a meta-analysis by Xiaoyan Liang, Jianghong Dai, Feifei Wang

    Published 2025-01-01
    “…Atrial fibrillation (AF) and atrial flutter have been more pronounced in patients with hyperglycemia. Sodium-glucose co-transporter 2 (SGLT2) inhibitors are now considered as second-line treatment for patients with T2DM following inadequate glycemic control with first line agents. …”
    Get full text
    Article
  7. 807
  8. 808
  9. 809
  10. 810
  11. 811
  12. 812
  13. 813
  14. 814
  15. 815
  16. 816
  17. 817
  18. 818
  19. 819
  20. 820